Acorda Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Acorda Therapeutics sits in the top decile of US sponsors by registered trial count (#467 of 15,742 sponsors by registered trial count).
Acorda Therapeutics: 36 sponsored US clinical trials, none currently recruiting.
Acorda Therapeutics sponsors 36 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 32 completed. 13 of these trials are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Idiopathic Parkinson´s Disease, with 2 trials.
Top-decile sponsor footprint
Acorda Therapeutics ranks in the top decile of sponsors by registered trial count (#467 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
32 of 36 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
36 total, page 1 of 1
Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
NCT03887884
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
NCT02905227
A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
NCT02807675
A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
NCT02812394
A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers
NCT02663999
A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma
NCT02633007
A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults
NCT02633839
Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
NCT02609945
Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)
NCT02474407
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
NCT02398461
Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
NCT02422940
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
NCT02242487
Randomized Safety Study of CVT-301 Compared to an Observational Control Group
NCT02352363
A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
NCT02271217
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.
NCT02316847
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
NCT02240030
A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure
NCT01944683
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
NCT01777555
A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial
NCT01839279
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
NCT01803867
A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
NCT01605825
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
NCT01535664
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
NCT01468350
A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode
NCT01417078
Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy
NCT01405950
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
NCT01328379
Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment
NCT01316055
Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure
NCT01258387
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
NCT00649792
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
NCT00483652
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
NCT00648908
Study of Oral Fampridine-SR in Multiple Sclerosis
NCT00127530
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
NCT00654927
Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
NCT00053417
Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury
NCT00041717
Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury
NCT01683838
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 7 |
| Phase 3 | 13 |
Therapeutic Areas
How the Acorda Therapeutics early-phase archive is shaped
36 indexed studies, none listed as recruiting (0% open); 32 completed (89%).
Phase mix: 13 late (III/IV) vs 22 early (I/II) (early-phase heavy).
Top condition: Idiopathic Parkinson´s Disease (2 trials), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Acorda Therapeutics: archived-pipeline peers nationwide
Peers matched on 36 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Acorda Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 36 archived trials
- Baystate Medical Center · 36 trials · 17% recruiting
- Eastern Virginia Medical School · 36 trials · 17% recruiting
- Enanta Pharmaceuticals · 36 trials · 3% recruiting
- MacroGenics · 36 trials · 11% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Acorda Therapeutics page
36 registered trials is a research-attention snapshot, not an endorsement of Acorda Therapeutics or any single study.
- None of Acorda Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Idiopathic Parkinson´s Disease is the condition Acorda Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Idiopathic Parkinson´s Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Acorda Therapeutics pipeline card: 36 registered trials from official public datasets.Report a data error.